20^th Global Biomarkers and Clinical Research Summit

Dr. Ramona D’Amico has completed master's degree in biology at the University of Messina in 2016. Dr. Ramona D’Amico has completed her PhD in Applied Biology and Experimental Medicine in the year 2020 by University of Messina. Additionally, she worked at Health Science Research Centre, Whiteland College, University of Roehampton in London (UK) and performed postdoctoral studies at University of Messina. She worked as researcher for studies on preclinical biochemical and pharmacology activities (in vitro primary cultures and in vivo experimental models), for the Epitech Group; she is also a research fellow in Biochemistry at Messina University. Now she is a Researcher in Clinical Biochemistry at the University of Messina. She has published more than 100 articles in reputed journals about biomarkers, molecular pathways, oxidative stress, inflammation and natural compound. Her research is involved in preclinical studies for the discovery of new biomarkers. Dr. Ramona D’Amico have knowledge about animals research, biochemical and molecular biology, immunohistochemical and immunofluorescence analysis.

Health Science Research

Master's degree in Biological Sciences, PhD in "Experimental Medicine", Associate Professor in Clinical Biochemistry and Clinical Molecular Biology at Messina University, Dpt of Chemical, Biological, Pharmaceutical and Environmental Sciences. She has an important research background in the fields of inflammation, neuroinflammation, oxidative stress, pain, immunity in specific area of biochemistry, pharmacology and neuroscience and nutrition

biochemistry, pharmacology, nutrition

Dr. M. Walid Qoronfleh is currently the Director of Healthcare Research and Policy at the World Innovation Summit for Health (WISH). Immediately prior to this he was Biotechnology Development Director at Hamad Bin Khalifa University - Qatar Biomedical Research Institute (HBKU-QBRI). He has over 20 years of scientific, technology, business, and commercial experience. He has held several senior management and executive positions with increasing responsibilities at GlaxoSmithKline (GSK), Sanofi, US_National Institutes of Health–National Cancer Institute (NIH-NCI), NextGen Sciences (VP, Personalized Medicine) and SDIX (Executive Director, Diagnostics business, Nasdaq: SDIX). Dr. Qoronfleh leads the WISH Doha-based research unit which is engaged in research areas that are of immediate global and local healthcare relevance to Qatar.The research is undertaken with a view to positively impacting health policy. These areas include autism, mental health, dementia, patient safety, cancer, diabetes & obesity, precision medicine and bioethics. Dr. Qoronfleh is the founder of three biotechnology companies and he is a co-founder and the managing director of the boutique consulting company Q3CG.

Biotechnology, Diagnostics, and Precision medicine /Healthcare

Dr. Búko has served as the Vice President of Human Metabolome Technologies-America (HMT-A) Biomarker discovery team since 2013, where he partners with biopharmaceutical companies to bring high resolution quantitative metabolomics profiling to pre-clinical and clinical studies. Prior to joining Human Metabolome Technologies, Dr. Búko was Senior Director Translational Medicine at Biogen for 10 years and Principal Investigator at Abbott labs for 18 years. He received his Ph.D. in Chemistry from the University of Virginia, with post-doctoral work for Bureau of Biologics and Biophysics at Food and Drug administration.

Dr. Búko’s career has focused primarily on omics solutions for biomarker and target discovery within the biopharma pipeline. Most of his work has been in immunology, infectious disease and neurology, however, at HMT-A he has widened his scope to many other therapeutic areas. While in biopharma Alex managed biomarker pipelines from pre-clinical to clinical studies using various protein and small molecule technologies to discovery and validate biomarkers for drug development and patient stratification. Dr. Búko’s areas of expertise include proteomics, lipidomics, metabolomics, protein assays and the statistical and biological pathway approaches required to combine omics data and generate prognostic and diagnostic algorithms.

Fred Baribaud holds a PhD from the University of Lausanne and has conducted postdoctoral studies at the University of Pennsylvania. He has worked at Incyte Corporation in a discovery role on target validation and as a compound team co-lead for small molecular inhibitors. For the past ten years, Fred has worked at Janssen R&D in Immunology Biomarkers on various inflammatory diseases. In his current role as Scientific Director he is focused on obtaining disease rational for targets and patient segmentation for inflammatory bowel diseases.

For the past ten years, Fred has worked at Janssen R&D in Immunology Biomarkers on various inflammatory diseases. In his current role as Scientific Director he is focused on obtaining disease rational for targets and patient segmentation for inflammatory bowel diseases.

Dr. Martin Burow is founder and owner of the DMB-Diagnostics GmbH and specialist for medical sales and marketing activities in Asia and Europe. Martin Burow has completed his PhD in Chemistry and Biochemistry at the University of Münster in 1993 and worked 3 years as a Post-doctoral fellow for the Ministry of International Trade and Industry at the National Institute of Materials and Chemical Research (NIMC) in Tsukuba, Japan. After his return to Germany, he started his career in the medical device industry and developed the Asian-Pacific markets for Brahms-Thermofisher in the field of medical diagnostics (thyroid, sepsis, prenatal and oncology). Later, he started his own company (DMB-Diagnostics GmbH) to introduce highly innovative diagnostics worldwide for better treatment standards for oncological patients.

Biochemistry, Diagnostics, Regulatory

Leveraging a proven experience, LOUIS CAZE provides cancer patients with a wide range of care services, including Counselling, Wellness, Pain Relief and Multidisciplinary Support. Louis Caze Supportive Care Center focuses on improving quality of life for Cancer patients and their families. Following a cancer diagnosis, it is normal for patients to experience burdensome physical symptoms and/or psychological distress from their disease and/or side effects of its treatment.

Optimize healing process : reduce stress and anxiety, strengthen physical condition (Dietary follow-up, sporting exercises...) Relieve suffering and improve quality of life: helping patients get relief from symptoms caused by cancer and treatment, like pain, nausea, fatigue, shortness of breath... Better inform patients and family members via a set of services that deal with emotional and social implications of cancer treatment

Sergey Suchkov, MD, PhD was born in 11.01.1957, a researcher-immunologist, a clinician, graduated from Astrakhan State Medical University, Russia, in 1980.Suchkov has been trained at the Institute for Medical Enzymology, The USSR Academy of Medical Sciences,National Center for Immunology (Russia), NIH, Bethesda, USA) and British Society for Immunology to cover 4 British university facilities. Since 2005, Dr Suchkov has been working as Faculty Professor of I.M. Sechenov First Moscow State Medical University and Of A.I.Evdokimov Moscow State Medical & Dental University. From 2007, Suchkov is the First Vice-President and Dean of the School of PPPM Politics and Management of the University of World Politics and Law. In 1991-1995, Dr Suchkov was a Scientific Secretary-in-Chief of the Editorial Board of the International Journal“Biomedical Science” (Russian Academy of Sciences and Royal Society of Chemistry, UK) and The International Publishing Bureau at the Presidium of the Russian Academy of Sciences. In 1995-2005, Suchkov was a Director of the Russian-American Program in Immunology of the Eye Diseases.Dr Suchkov is a member of EPMA (European Association of Predictive, Preventive and Personalized Medicine,Brussels-Bonn), a member of the NY Academy of Sciences, a member of the Editorial Boards for Open Journal of Immunology and others. Dr Suchkov is known as an author of the Concept of post-infectious clinical and immunological syndrome, co-author of a concept of abzymes and their impact into the pathogenesis of autoimmunity conditions, and as one of the pioneers in promoting the Concept of PPPM into a practical branch of health services.

Predictive, Preventive and Personalized Medicine, Immunology, Medicine, Pathology

Dr. Hoque is an Associate Professor of Otolaryngology-Head & Neck Surgery, Urology and Oncology at Johns Hopkins University School of Medicine. Dr. Hoque completed dental and oral surgery training at the Dhaka Dental College, Dhaka University, Bangladesh. He then moved to Japan for the completion of Ph.D degree, where he also completed Advanced Clinical Training in Oral and Maxillofacial Surgery and Oncology. After training in Japan, he worked in the Head and Neck Cancer Research Division as a Postdoctoral Fellow under the mentorship of Dr. David Sidransky. He joined as a faculty member in 2006 in the Department of Otolaryngology-Head and Neck Surgery. His research interests includes: a) To understand molecular biologic basis of head and neck, lung and genitourinary cancer b) To develop and validate genetic and epigenetic approach for early cancer diagnosis, cancer risk assessment and cancer prognosis and c) To identify molecular alterations due to environmental exposures such as active smoking, passive smoking and arsenic.

Develop and validate genetic and epigenetic approach for early cancer diagnosis, cancer risk assessment and cancer prognosis; Molecular biologic basis of head and neck, lung and genitourinary cancer.

Zhigang Kang has completed his PhD from University of Helsinki, Finland and Post-doctoral studies from NIMH, NIH. He is a Research Scientist in Molecular Target Core, Genetics Branch, Center for Cancer Research, National Cancer Institute and an employee of Basic Science Program, Leidos Biomedical Research, Inc., Frederick. He has been working in the field of cancer biomarkers for the past 7 years. His research interests focus on the detection of invasive tumor biomarkers include circulating tumor cell (CTC), cell free circulating tumor DNA and clinical relevance protein markers from peripheral blood of patients with various types of tumors.

His research interests focus on the detection of invasive tumor biomarkers include circulating tumor cell (CTC), cell free circulating tumor DNA and clinical relevance protein markers from peripheral blood of patients with various types of tumors.

David I Smith completed his Ph.D. at the age of 23 years from the University of Wisconsin in Madison and then did post-doctoral studies at the University of California in Irvine. Since 1996 he has been a Professor at the Mayo Clinic in the Department of Laboratory Medicine and Pathology. He is also the Chairman of the Technology Assessment Group for the Center for Individualized Medicine at the Mayo Clinic. His laboratory studies the common fragile sites and the role that these regions of instability play in the development of cancer. His group also studies the different ways that HPV can contribute to the development of different cancers. He has published over 200 papers in reputed journals and serves on the Editorial Board of a number of journals.

His group also studies the different ways that HPV can contribute to the development of different cancers. He has published over 200 papers in reputed journals and serves on the Editorial Board of a number of journals.

Dimitrios H. Roukos is currently working as Founding Director, Centre for Biosystems & Synthetic Genomic Network Medicine - CBS. GenNetMed Ioannina University- Ioannina, Greece. He is also Leader at Translational Research, European Network of Excellence (EUNE) for Gastric Cancer (since 2006) and affiliated to Department of Surgery, Ioannina University Hospital , Ioannina , Greece (since 1990). Dr. D. Roukos has graduated from Athens University School of Medicine, Greece. He underwent specialist training in surgery at the J.W.Goethe-University Hospital in Frankfurt a.M., Germany where received his Doctorate (Dr.med). He moved back to Greece and since 1990 works at the Ioannina University School of Medicine.

Genetics, Pathology, Biomarkers, Systems biology & and cancer networks